Adding rituximab to cyclophosphamide, vincristine and prednisone increases time to treatment failure or progression in people with untreated stage III/IV follicular lymphoma

References 

1. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–1423
   • MEDLINE
   • CrossRef
2. Dreyling M, Forstpointner R, Ludwig W, et al. The addition of rituximab to fludarabine combination (R-FCM) significantly improves remission rates and overall survival in recurrent follicular as well as mantle cell lymphoma – follow-up of a prospective randomized trial of the german low grade lymphoma study group (GLSG). Ann Oncol. 2005;16(110):abstract 252
3. Hiddeman W, Forstpointer R, Kneba M, et al. The addition of rituximab with chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymphoma but not in mantle cell lymphoma: results of two prospective randomized studies of the german low grade study group (GLSG). Blood. 2004;104(50a):abstract 161
4. Herold M, Pasold R, Srock S, et al. Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin’s lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood. 2004;104(169a):abstract 584
5. Ghielmini M, Hsu-Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103:4416–4423
   • MEDLINE
   • CrossRef